{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carcinome endométrioïde : Questions médicales les plus fréquentes",
"headline": "Carcinome endométrioïde : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carcinome endométrioïde : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-19",
"dateModified": "2026-05-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carcinome endométrioïde"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'ovaire",
"url": "https://questionsmedicales.fr/mesh/D010051",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'ovaire",
"code": {
"@type": "MedicalCode",
"code": "D010051",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.391.630.705"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carcinome endométrioïde",
"alternateName": "Carcinoma, Endometrioid",
"code": {
"@type": "MedicalCode",
"code": "D018269",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Antonio Travaglino",
"url": "https://questionsmedicales.fr/author/Antonio%20Travaglino",
"affiliation": {
"@type": "Organization",
"name": "Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy; Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy."
}
},
{
"@type": "Person",
"name": "Antonio Raffone",
"url": "https://questionsmedicales.fr/author/Antonio%20Raffone",
"affiliation": {
"@type": "Organization",
"name": "Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy."
}
},
{
"@type": "Person",
"name": "Martin Köbel",
"url": "https://questionsmedicales.fr/author/Martin%20K%C3%B6bel",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Hiroshi Yoshida",
"url": "https://questionsmedicales.fr/author/Hiroshi%20Yoshida",
"affiliation": {
"@type": "Organization",
"name": "Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. hiroyosh@ncc.go.jp."
}
},
{
"@type": "Person",
"name": "Mitsuya Ishikawa",
"url": "https://questionsmedicales.fr/author/Mitsuya%20Ishikawa",
"affiliation": {
"@type": "Organization",
"name": "Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Patterns of spread and genetic alterations of primary endometrioid carcinomas of the ovary.",
"datePublished": "2023-09-04",
"url": "https://questionsmedicales.fr/article/37567599",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/ijgc-2023-004627"
}
},
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation Signature of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37652400",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.modpat.2023.100321"
}
},
{
"@type": "ScholarlyArticle",
"name": "p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.",
"datePublished": "2024-05-09",
"url": "https://questionsmedicales.fr/article/39164940",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PGP.0000000000001012"
}
},
{
"@type": "ScholarlyArticle",
"name": "ROLE OF STROMAL MICROENVIRONMENT IN THE FORMATION OF INVASIVE, ANGIOGENIC, AND METASTATIC POTENTIAL OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37417282",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.15407/exp-oncology.2023.01.051"
}
},
{
"@type": "ScholarlyArticle",
"name": "Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.",
"datePublished": "2023-10-20",
"url": "https://questionsmedicales.fr/article/37859432",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PAI.0000000000001170"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Troubles gonadiques",
"item": "https://questionsmedicales.fr/mesh/D006058"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladies ovariennes",
"item": "https://questionsmedicales.fr/mesh/D010049"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs de l'ovaire",
"item": "https://questionsmedicales.fr/mesh/D010051"
},
{
"@type": "ListItem",
"position": 6,
"name": "Carcinome endométrioïde",
"item": "https://questionsmedicales.fr/mesh/D018269"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carcinome endométrioïde - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carcinome endométrioïde",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carcinome endométrioïde",
"description": "Comment diagnostique-t-on un carcinome endométrioïde ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes peuvent indiquer un carcinome endométrioïde ?\nLe dépistage est-il recommandé ?\nQuel rôle joue l'histopathologie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carcinome endométrioïde",
"description": "Quels sont les symptômes courants du carcinome endométrioïde ?\nLes pertes vaginales peuvent-elles être un symptôme ?\nLa fatigue est-elle un symptôme associé ?\nLes douleurs pendant les rapports sexuels sont-elles fréquentes ?\nPeut-on avoir des symptômes sans saignements ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carcinome endométrioïde",
"description": "Peut-on prévenir le carcinome endométrioïde ?\nLe contrôle du poids peut-il réduire le risque ?\nLes contraceptifs hormonaux aident-ils à prévenir ce cancer ?\nFaut-il surveiller les antécédents familiaux ?\nL'exercice physique a-t-il un impact sur le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carcinome endométrioïde",
"description": "Quels traitements sont disponibles pour ce cancer ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés en chimiothérapie ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carcinome endométrioïde",
"description": "Quelles sont les complications possibles du carcinome endométrioïde ?\nLe carcinome endométrioïde peut-il affecter la fertilité ?\nY a-t-il des risques de récidive après traitement ?\nLes métastases sont-elles possibles ?\nQuels effets secondaires peuvent survenir avec le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carcinome endométrioïde",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle dans le risque ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe syndrome des ovaires polykystiques est-il un facteur de risque ?\nLes traitements hormonaux peuvent-ils influencer le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018269#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un carcinome endométrioïde ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par biopsie de l'endomètre et imageries comme l'échographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'échographie transvaginale et l'IRM pour évaluer l'extension."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un carcinome endométrioïde ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements vaginaux anormaux et des douleurs pelviennes peuvent indiquer ce cancer."
}
},
{
"@type": "Question",
"name": "Le dépistage est-il recommandé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de dépistage systématique, mais un suivi régulier est conseillé pour les femmes à risque."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'histopathologie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'histopathologie permet d'analyser les tissus et de confirmer la présence de cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du carcinome endométrioïde ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements vaginaux irréguliers et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les pertes vaginales peuvent-elles être un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des pertes vaginales anormales peuvent être un signe de carcinome endométrioïde."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut survenir en raison de l'anémie liée aux saignements."
}
},
{
"@type": "Question",
"name": "Les douleurs pendant les rapports sexuels sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs pendant les rapports peuvent être un symptôme du carcinome endométrioïde."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignements ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes sans saignements vaginaux."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le carcinome endométrioïde ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "Le contrôle du poids peut-il réduire le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir un poids santé peut réduire le risque de développer ce type de cancer."
}
},
{
"@type": "Question",
"name": "Les contraceptifs hormonaux aident-ils à prévenir ce cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains contraceptifs hormonaux peuvent réduire le risque de carcinome endométrioïde."
}
},
{
"@type": "Question",
"name": "Faut-il surveiller les antécédents familiaux ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents familiaux de cancer de l'utérus nécessitent une surveillance accrue."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut aider à réduire le risque de cancer de l'utérus."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour ce cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et la chimiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour enlever la tumeur et évaluer l'extension."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés en chimiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme le carboplatine et le paclitaxel sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être efficace pour réduire la taille des tumeurs et prévenir les récidives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés sont en développement, mais leur utilisation dépend du stade du cancer."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du carcinome endométrioïde ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation du cancer et des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Le carcinome endométrioïde peut-il affecter la fertilité ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement et la maladie peuvent affecter la fertilité des femmes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive après traitement ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de récidive dépend du stade et du type de traitement reçu."
}
},
{
"@type": "Question",
"name": "Les métastases sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le carcinome endométrioïde peut se propager à d'autres organes, comme les ovaires."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec le traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent la fatigue, les nausées et les changements hormonaux."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le diabète et des antécédents familiaux de cancer."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après la ménopause."
}
},
{
"@type": "Question",
"name": "Les antécédents de cancer augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents de cancer du sein ou de l'ovaire augmente le risque."
}
},
{
"@type": "Question",
"name": "Le syndrome des ovaires polykystiques est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ce syndrome est associé à un risque accru de carcinome endométrioïde."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux peuvent-ils influencer le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements hormonaux peuvent augmenter le risque de ce cancer."
}
}
]
}
]
}
Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy; Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy.
Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.
Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.
Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.
Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bam-bino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy; Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy. Electronic address: Gianfranco.zannoni@unicatt.it.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China. lileigh@163.com.
Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
The primary objective was to characterize the rate of lymph node involvement in a cohort of patients with primary ovarian endometrioid adenocarcinoma. Additionally, we sought to quantify the recurrenc...
Patients diagnosed with primary endometrioid adenocarcinoma of the ovary without synchronous carcinomas of the female genital tract between 2012 and 2021 were identified. Demographic and disease-relat...
Sixty-three patients met inclusion criteria. Median age was 60 (range 22-90) years. Histologic grade was 1 in 20 (32%), 2 in 27 (43%), and 3 in 16 (25%) tumors. International Federation of Gynecology ...
There were no lymph node metastases in patients with comprehensively staged primary endometrioid ovarian carcinoma. Staging did not impact survival and may be omitted, regardless of grade. Germline BR...
Among the 4 molecular subgroups of endometrial carcinoma, the p53 abnormal (copy number high) subgroup has the worst prognosis; however, the histologic characteristics of this subgroup are not well es...
The aim of the study was to determine the association of indicators of the progression of endometrioid carcinoma of the endometrium (ECE) with the type of stromal microenvironment, the counts of CXCL1...
Histological preparations of ECE samples (n = 51) were analyzed. Expression of CXCL2 and CXCR4 antigens in tumor cells, the content of CXCL12+ fibroblasts and CD163+ macrophages, and the density of mi...
Groups of ECE with desmoplastic and inflammatory stromal reactions were delineated. The majority (80.0%) of tumors with desmoplasia were of low differentiation grade, deeply invading the myometrium; 6...
The obtained results showed that the morphological architecture of the stromal ECE component is related to the molecular features of its constituents and tumor cells. Their interaction modulates the p...
Recently, the US Food and Drug Administration (FDA) approved the Ventana MMR RxDx Panel as the first immunohistochemical companion diagnostic test for identification of tumors with mismatch repair (MM...
Endometrial cancer is the most prevalent form of cancer affecting female reproductive organs. The most common histologic type, endometrioid carcinoma, accounts for 75-80% of all endometrial cancer cas...
A total of 160 formalin-fixed paraffin-embedded samples were included in this study (50 cases of endometrial atypical hyperplasia, 50 cases of endometrioid endometrial carcinoma, 30 cases of prolifera...
A decreasing pattern of immunopositivity for DKK1, E-cadherin and β-catenin from proliferative/secretory endometrium to endometrial atypical hyperplasia and endometrioid carcinoma was found. Increasin...
Decreasing DKK1 positivity from benign endometrium to endometrioid carcinoma suggests a negative regulatory function of DKK1 in endometrioid carcinoma. DKK1 is downregulated in the Wnt signalling path...
Ovarian mesonephric-like adenocarcinoma (MLA) is a rare tumor with potential origins in endometriosis and Müllerian-type epithelial tumors. The morphologic patterns of MLA overlap with those of endome...
The objective of this study was to investigate the prognostic significance of the depth of cervical stromal invasion (CSI) in women with FIGO stage II uterine endometrioid adenocarcinoma (EC)....
Our database of women with EC was quired for patients with stage II EC. Pathologic slides were retrieved and reviewed by gynecologic pathologists to determine cervical stromal thickness and depth of C...
A total of 117 patients were included in our study who had hysterectomy between 1/1990 and 8/2021. Seventy-nine patients (68%) with <50% and 38 (32w%) with ≥50% CSI. After a median follow-up of 131 mo...
Our results suggest that deep CSI is not an independent prognostic factor for survival endpoints in women with stage II uterine endometroid adenocarcinoma. The lack of independent prognostic significa...
The aim of this study was to assess the disease-free survival (DFS) and overall survival (OS) of patients with grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary, according to s...
Multicenter, retrospective, observational cohort study. Patients with endometrioid ovarian carcinoma, surgical procedure performed between May 1985 and December 2019, stage pT1 N0/N1/Nx, grade 1-2 wer...
298 patients were included. 199 (66.8 %) patients underwent lymph node assessment. Of these, 166 (83.4 %) had unilateral/bilateral pelvic and para-aortic/caval lymphadenectomy. Eleven (5.5 %) patients...
Staging lymphadenectomy in grade 2 endometrioid ovarian carcinoma patients was associated with improved DFS and OS. Grade 1 and grade 2 might be considered as two different entities, which could benef...
With the advancement of diagnostic molecular technology and the molecular classification of endometrial endometrioid carcinoma (EEC), it remains to be seen whether conventional International Federatio...